Local view for "http://purl.org/linkedpolitics/eu/plenary/2006-05-31-Speech-3-176"

Predicate	Value (sorted: default)
rdf:type	lpv_eu:Speech2
dcterms:Date	"2006-05-31"^^xsd:date2
dcterms:Is Part Of	lp_eu:Medicinal products for paediatric use (debate)2
dcterms:Language	"de"^^xsd:language2
lpv:document identification number	"en.20060531.16.3-176"2
lpv:hasSubsequent	lp_eu:2006-05-31-Speech-3-1782
lpv:speaker	lp:Günter Verheugen2
lpv:translated text	"Considering the risks of substances that are carcinogenic, mutagenic, or toxic to reproduction, the Commission shall appoint the Committee for Medicinal Products for Human Use of the European Agency for the Evaluation of Medicinal Products to formulate an opinion on the use of these categories of substance as auxiliary agents in medicinal products for human use; the legal basis for this is Article 5(3) and Article 57(1)(p) of Regulation (EC) No 726/2004 of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency. The Commission shall forward the opinion of the Committee for Medicinal Products for Human Use to the European Parliament and to the Council. Within six months of the delivery of the opinion by the Committee for Medicinal Products for Human Use, the Commission shall inform the European Parliament and the Council about the measures that it plans to put in place following this opinion."@en1
lpv:unclassifiedMetadata	"(The wording of these three paragraphs was expressly approved by the Commission and contains the Commission’s declaration on CMR substances)."1

Named graphs describing this resource:

The resource appears as object in 2 triples

Context graph